| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/10/2001 | WO2001032910A2 27 human secreted proteins |
| 05/10/2001 | WO2001032900A1 Method for transfer of molecular substances with prokaryontic nucleic acid-binding proteins |
| 05/10/2001 | WO2001032891A2 Human lipase |
| 05/10/2001 | WO2001032885A2 Human lipase |
| 05/10/2001 | WO2001032882A2 Nucleic acids and proteins from group b streptococcus |
| 05/10/2001 | WO2001032859A1 Novel tumor suppressor gene |
| 05/10/2001 | WO2001032830A2 Process for producing, methods and compositions of glucuronoxylomannan as nutriceutical agent from higher basidiomycetes mushroom |
| 05/10/2001 | WO2001032706A2 Novel human transporter proteins and polynucleotides encoding the same |
| 05/10/2001 | WO2001032690A1 Substituted dipeptides having nos inhibiting activity |
| 05/10/2001 | WO2001032685A2 Gene expression directed by a super-psa promoter |
| 05/10/2001 | WO2001032683A1 Production of polymorphic forms i and ii of finasteride by complexation with group i or ii metal salts |
| 05/10/2001 | WO2001032680A2 18-nor-steroids as selectively active estrogens |
| 05/10/2001 | WO2001032677A1 Uteroglobin-like polynucleotides, polypeptides, and antibodies |
| 05/10/2001 | WO2001032675A1 32 human secreted proteins |
| 05/10/2001 | WO2001032674A1 26 human secreted proteins |
| 05/10/2001 | WO2001032670A1 Oxetanone derivatives |
| 05/10/2001 | WO2001032669A1 Oxetanone derivatives |
| 05/10/2001 | WO2001032667A1 Ether-type gla-60 analogues |
| 05/10/2001 | WO2001032663A2 Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same |
| 05/10/2001 | WO2001032660A1 Compounds having 5-ht6 receptor antagonist activity |
| 05/10/2001 | WO2001032659A1 Isoquinoline and quinazoline derivatives for the treatment of cns disorders |
| 05/10/2001 | WO2001032657A1 Antibiotic sultam and sultone derived oxazolidinones |
| 05/10/2001 | WO2001032656A1 Polymorphic form of a tachykinin receptor antagonist |
| 05/10/2001 | WO2001032655A2 Quinoline and naphthyridine carboxylic acid antibacterials |
| 05/10/2001 | WO2001032654A2 Novel heterocyclic compounds and their use as medicines |
| 05/10/2001 | WO2001032653A1 Heterocyclic substituted pyrazolones |
| 05/10/2001 | WO2001032652A2 N-substituted carbamoyloxyalkyl-azolium derivatives |
| 05/10/2001 | WO2001032651A1 Quinazoline derivatives as vegf inhibitors |
| 05/10/2001 | WO2001032650A2 Alkaline salts of n-(6-alkyl-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinesulfone)-n'-isonicotinoylhydrazide, possess for their preparation, and pharmaceutical composition based on these salts |
| 05/10/2001 | WO2001032649A1 Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof |
| 05/10/2001 | WO2001032648A1 Novel cyclopropanes as cgrp antagonists, medicaments containing said compounds and method for the production thereof |
| 05/10/2001 | WO2001032647A2 Benz`f!indoles for use in the treatment of 5ht receptor related disorders |
| 05/10/2001 | WO2001032646A2 Sulfonamide derivatives |
| 05/10/2001 | WO2001032640A1 1-cyclic amino-alkylcyclohexane compounds, pharmaceutical compositions thereof, and their use as anticonvulsants |
| 05/10/2001 | WO2001032639A1 Nonpeptide substituted benzothiazepines as vasopressin antagonists |
| 05/10/2001 | WO2001032638A1 Indeno-, naphtho-, and benzocyclohepta-dihydrothiazole derivatives, the production thereof and their use as anorectic medicaments |
| 05/10/2001 | WO2001032634A1 2-cyclohexyl benzimidazole nmda/nr2b antagonists |
| 05/10/2001 | WO2001032633A1 Substituted 5-benzyl-2,4-diaminopyrimidines |
| 05/10/2001 | WO2001032631A2 Heterocyclic cytotoxic agents |
| 05/10/2001 | WO2001032630A1 Oligobenzimidazole derivatives and their use as dna transfection agents |
| 05/10/2001 | WO2001032629A1 1-benzylpyrazoles-3-carboxylic acid tricyclic derivatives as cannabinoid receptor antagonists |
| 05/10/2001 | WO2001032627A1 Process of making substituted pyrazoles |
| 05/10/2001 | WO2001032626A1 Isoquinoline and quinazoline derivatives having a combined 5ht1a, 5ht1b and 5ht1d receptor activity |
| 05/10/2001 | WO2001032625A1 Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
| 05/10/2001 | WO2001032624A1 4-phenyl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
| 05/10/2001 | WO2001032622A1 Positive modulators of nicotinic receptor agonists |
| 05/10/2001 | WO2001032621A1 Novel indole derivatives and drugs containing the same as the active ingredient |
| 05/10/2001 | WO2001032620A1 Positive modulators of nicotinic receptor agonists |
| 05/10/2001 | WO2001032619A1 Positive modulators of nicotinic receptor agonists |
| 05/10/2001 | WO2001032618A1 Pyrrole derivatives as phosphodiesterase vii inhibitors |
| 05/10/2001 | WO2001032616A2 Oxetanone derivatives |
| 05/10/2001 | WO2001032615A1 1,4 substituted piperidinyl nmda/nr2b antagonists |
| 05/10/2001 | WO2001032614A2 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof |
| 05/10/2001 | WO2001032611A1 N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them |
| 05/10/2001 | WO2001032608A1 Process for the preparation of oxyiminoalkanoic acid derivatives |
| 05/10/2001 | WO2001032606A1 Compounds having mif antagonist activity |
| 05/10/2001 | WO2001032604A1 Activators of soluble guanylate cyclase |
| 05/10/2001 | WO2001032602A1 Diaryl-enynes |
| 05/10/2001 | WO2001032601A1 Polymorphic forms of sertraline hydrochloride |
| 05/10/2001 | WO2001032596A1 Phenoxy carboxylic acid compounds and compositions for delivering active agents |
| 05/10/2001 | WO2001032264A1 Aryl olefinic azacyclic, and aryl acetylenic azacyclic compounds, pharmaceutical compositions containing them and their use as inhibitors of nicotinic cholinergic receptors |
| 05/10/2001 | WO2001032263A1 Use of dopamine-d3 receptor agonists for the therapy of salt-dependent hypertension |
| 05/10/2001 | WO2001032224A1 Method of inactivating pathogens |
| 05/10/2001 | WO2001032219A2 Treatment of c. difficile toxin b associated conditions |
| 05/10/2001 | WO2001032217A2 Pharmacological inducement of the fed mode for enhanced drug administration to the stomach |
| 05/10/2001 | WO2001032216A2 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance |
| 05/10/2001 | WO2001032215A1 Antiviral agent for use in treatment of cancer |
| 05/10/2001 | WO2001032214A1 Inhibitors against vascular lipid deposition containing chymase-inhibiting substances |
| 05/10/2001 | WO2001032212A1 Drugs, drinks or foods |
| 05/10/2001 | WO2001032210A2 Compositions for treating atheroma and neoplastic tissue |
| 05/10/2001 | WO2001032202A1 Use of nitric oxide for the treatment of airway constriction |
| 05/10/2001 | WO2001032198A1 Prevention and treatment of biomaterial-associated infections |
| 05/10/2001 | WO2001032191A2 Phytoestrogenic pharmaceutical preparations |
| 05/10/2001 | WO2001032187A1 INHIBITING FtsZ PROTEIN (DE)POLYMERISATION |
| 05/10/2001 | WO2001032186A2 Inhibitors of the inositol polyphosphate 5-phosphatase ship2 molecule |
| 05/10/2001 | WO2001032185A1 A pharmaceutical composition containing bisphosphonic acid(s) or salt(s) thereof and a process of preparing thereof |
| 05/10/2001 | WO2001032184A2 Abc1 modulation for the modulation of cholesterol transport |
| 05/10/2001 | WO2001032183A2 Pharmaceutical compositions comprising oxcarbazepine |
| 05/10/2001 | WO2001032182A1 Us0027324for eating disorders |
| 05/10/2001 | WO2001032181A2 Pharmaceutical compositions containing a fluoroquinolone antibiotic drug and xanthan gum |
| 05/10/2001 | WO2001032180A2 Composition for treatment of constipation and irritable bowel syndrome |
| 05/10/2001 | WO2001032179A1 8-aza-bicyclo[3.2.1]octane nmda/nr2b antagonists |
| 05/10/2001 | WO2001032178A1 Use of 3,4-substituted piperidines |
| 05/10/2001 | WO2001032177A1 2-aza-bicyclo[2.2.2]octane nmda/nr2b antagonists |
| 05/10/2001 | WO2001032176A1 Beta-carboline derivatives for use as analgesics |
| 05/10/2001 | WO2001032175A1 Isoxazole derivatives to be used as phosphodiesterase vii inhibitors |
| 05/10/2001 | WO2001032174A1 2-benzyl and 2-heteroaryl benzimidazole nmda/nr2b antagonists |
| 05/10/2001 | WO2001032173A1 Kainic acid neurocytotoxicity inhibitors |
| 05/10/2001 | WO2001032172A1 Process for formulation of carbapenem antibiotic compositions |
| 05/10/2001 | WO2001032171A1 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline nmda/nr2b antagonists |
| 05/10/2001 | WO2001032170A1 Composition and method for decreasing neurologic symptomatology |
| 05/10/2001 | WO2001032169A1 Agonists specific for the peripheral cannabinoid receptor |
| 05/10/2001 | WO2001032168A1 Method of treating benign forgetfulness |
| 05/10/2001 | WO2001032167A1 Endogenous nitric oxide synthesis under conditions of low oxygen tension |
| 05/10/2001 | WO2001032166A1 NEW COMBINATION COMPRISING A β2-ADRENORECEPTOR AGONIST AND A LEUKOTRIENE RECEPTOR ANTAGONIST |
| 05/10/2001 | WO2001032165A1 Method for administering a phosphodiesterase 4 inhibitor |
| 05/10/2001 | WO2001032164A1 Inhibitor for 20-hete-yielding enzyme |
| 05/10/2001 | WO2001032163A1 NEW COMBINATION COMPRISING A BETA 2 (β)2 ADRENO RECEPTOR AGONIST AND A LENKOTRIENE RECEPTOR ANTAGONIST |
| 05/10/2001 | WO2001032162A1 Liver selective therapy |
| 05/10/2001 | WO2001032161A2 Use of a hmg-coa reductase inhibitor for treating amyloid beta precursor disorders |